Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aztreonam inhalation - Gilead Sciences

Drug Profile

Aztreonam inhalation - Gilead Sciences

Alternative Names: AI - Gilead; AZLI; Aztreonam lysine; Cayston; Corus 1020; GS-9268

Latest Information Update: 18 Aug 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Class Antibacterials; Monobactams; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis-associated respiratory tract infections
  • Discontinued Bronchiectasis; Burkholderia infections

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 03 Aug 2017 Phase-III clinical trials in Cystic fibrosis-associated respiratory tract infections (In adolescents, In children, In infants) in Spain (Inhalation) (EudraCT2016-002749-42) (NCT03219164)
  • 03 Aug 2017 Phase-III clinical trials in Cystic fibrosis-associated respiratory tract infections (In children, In infants, In adolescents) in USA (Inhalation) (NCT03219164)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top